Cargando…
Switching biological disease-modifying antirheumatic drugs in patients with axial spondyloarthritis: results from a systematic literature review
OBJECTIVES: First, to investigate if switching biological disease-modifying antirheumatic drugs (bDMARDs) after the failure to prior bDMARD is efficacious in patients with axial spondyloarthritis (axSpA). Second, to evaluate the influence on this efficacy of (1) the reason to discontinue prior tumou...
Autores principales: | Navarro-Compán, Victoria, Plasencia-Rodríguez, Chamaida, de Miguel, Eugenio, Diaz del Campo, Petra, Balsa, Alejandro, Gratacós, Jordi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5640114/ https://www.ncbi.nlm.nih.gov/pubmed/29071119 http://dx.doi.org/10.1136/rmdopen-2017-000524 |
Ejemplares similares
-
Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAI
por: Marona, Jose, et al.
Publicado: (2020) -
Patient‐Reported Impact of Axial Spondyloarthritis on Working Life: Results From the European Map of Axial Spondyloarthritis Survey
por: Garrido‐Cumbrera, Marco, et al.
Publicado: (2021) -
Test–retest reliability of outcome measures: data from three trials in radiographic and non-radiographic axial spondyloarthritis
por: Boel, Anne, et al.
Publicado: (2021) -
Impact of axial spondyloarthritis on mental health in Europe: results from the EMAS study
por: Garrido-Cumbrera, Marco, et al.
Publicado: (2021) -
Development of a web-based decision aid for initiating biological or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in axial spondyloarthritis
por: Beckers, Esther, et al.
Publicado: (2023)